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Abstract
Background—Lung cancer is one of the leading cancer sites diagnosed among Asian 
Americans, Pacific Islanders, and Native Hawaiians (AANHPI). To better understand the patterns 
of lung cancer incidence among AANHPIs, we examined the incidence trends of five histologic 
cell types of lung cancer across ten AANHPI populations in comparison with non-Hispanic 
Whites.
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Methods—Lung cancer incidence data from 1990 through 2010 were obtained from 13 U.S. 
population-based cancer registries. Age-adjusted histologic cell-type–specific incidence rates and 
95% confidence intervals were calculated. Joinpoint regression models and annual percentage 
change (APC) statistics were used to characterize the magnitude and direction of trends.
Results—From 1990 through 2010, incidence rates of adenocarcinoma increased significantly 
for Filipino and Korean women with a 2.6% and 3.0% annual percentage increase, respectively. 
More recently, a significant rise in the incidence of adenocarcinoma was observed for Chinese 
men (1996–2010; APC = 1.3%). Squamous cell carcinoma (SCC) increased 2.4% per year among 
Japanese women. For SCC, small cell lung carcinoma, large cell and other specified carcinoma, 
and unspecified types, stable or decreasing trends were observed in most AANHPI groups and 
non-Hispanic Whites.
Conclusions—AANHPIs demonstrate a range in the burden of lung cancer across histologies 
and specific populations.
Impact—These findings illustrate the importance of disaggregating AANHPIs into their specific 
populations. The rise in incidence of adenocarcinoma and SCC among certain AANHPIs 
demonstrates the need for research into non-tobacco associated risk factors for these populations 
and targeted efforts for tobacco prevention.
Introduction
Asian Americans are the fastest growing racial/ethnic group in the United States (1–3), 
reaching more than 17 million in the 2010 Census (2, 3). In the first nationwide report of 
cancer incidence trends among specific Asian American populations, our group identified 
lung cancer as one of the top four cancers diagnosed among these populations from 1990 
through 2008 (4). Lung cancer was consistently the leading cancer diagnosis among 
Kampuchean men and the third ranking cancer diagnosed among Chinese, Filipina, and 
Japanese women (4). Moreover, although non-Hispanic Whites (NHW) demonstrated a 
decline in the incidence of lung cancer, such a decline was not observed in any Asian 
American population. Notably, increasing incidence trends of lung cancer were observed 
among South Asian men and Filipina and Korean women (4).
Native Hawaiians and pacific islanders are a small but growing population in the United 
States (5). Lung cancer was among the top three cancer sites in these populations from 1990 
through 2008 (6). Although both Native Hawaiian men and women demonstrated steady 
declines in the incidence rates of lung cancer (6), Native Hawaiian and Samoan men 
consistently displayed higher incidence rates in comparison with NHW (6).
It is well known that tumor histology plays an important role in lung cancer etiology and 
prognosis. The incidence rates of the histologic subtypes vary (7–10) due to differences in 
exposure of smoking and other lung carcinogens. Because of decreased smoking behavior, 
from 1992 through 2005, the overall incidence trends of squamous cell carcinoma (SCC), 
lung adenocarcinoma, and small cell carcinoma declined in the United States, with more 
rapid declines observed for SCC than adenocarcinoma (11). Yet, there is little information 
on these detailed histologic trends across specific racial/ethnic populations. This is 
particularly relevant for Asian American, Native Hawaiian, and Pacific Islander (AANHPI) 
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populations such as Koreans, Vietnamese, and Samoans, who have persistently high 
prevalence of smoking (12, 13), and for particular AANHPI women, such as Chinese 
women, who have an exceedingly low prevalence of smoking yet a high burden of lung 
adenocarcinoma (14).
To further understand the patterns of lung cancer incidence across AANHPIs, we examined 
the incidence trends of lung cancer by five histologic cell types across ten AANHPI 
populations by gender. The assembly of nationwide population-based histologic-specific 
incidence data by the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER) Program enables a high quality and comprehensive investigation across 
these important populations with varying incidence rates of disease.
Materials and Methods
Cancer incidence data
Cancer incidence data for all invasive lung cancers (excluding mesothelioma, Kaposi 
Sarcoma, and lymphomas and leukemias) during the 21-year period from 1990 through 2010 
were obtained from 13 U.S. population-based SEER cancer registries (Table 1). Histologic 
cell types were classified as defined by Lewis and colleagues (15) for small cell lung cancer 
(“SCLC”), adenocarcinoma, “SCC”, large cell and other specified carcinoma (“LC+OSC”), 
and unspecified malignant neoplasms (“unspecified”). A total of 100 AANHPI cases and 
1,475 NHW cases specified as a noncarcinoma or seemed to be a metastasis were excluded. 
The SEER registries cover 50.4% of the Asian American population and 66.5% of the NHPI 
population (16).
SEER data on race and Hispanic ethnicity were generally based on patients’ medical records 
(17, 18). AANHPIs were included in this analysis regardless of Hispanic ethnicity. 
Information on birthplace and surname was used when a specific race designation was 
lacking (19). Nonetheless, approximately 4.7% (increase of 0.16% in 1990 to 7.4% in 2010) 
of the AANHPI lung cancer cases were classified as “other Asian; Asian, not otherwise 
specified” and could not be included in a specific AANHPI category. Asian Indians and 
Pakistanis were combined on the basis of SEER coding.
Population data
Detailed population data for AANHPI populations are available from decennial U.S. 
censuses. Individuals could report a single race in the 1990 Census and multiple races in the 
2000 and 2010 Censuses; due to this incompatibility, we developed the following 
methodology for producing a consistent set of denominators. April 1, 1990, April 1, 2000, 
and April 1, 2010 Census population distributions by age, sex, and detailed AANHPI race/
ethnicity of a given geography were applied as percentages to the mid-year (July) estimates 
to yield estimates for the AANHPI populations. Because the 1990 Census did not publish 
county-level population counts for Pakistanis, we used the 1990 public-use microdata 
samples (20). The April 2000 and April 2010 estimates were derived by calculating an 
average of the single race alone count (i.e., those who self-identified with one AANHPI 
population) and the count for single race alone or in combination with other race(s). 
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Intercensal estimates were developed from linear interpolation between the three censuses. 
Because of the high percentage of AANHPIs of mixed ethnicity in Hawaii, as well as 
concerns that the NH population has been undercounted in previous censuses, the Hawaii 
Tumor Registry has developed improved population estimates derived from sample survey 
data collected by the Hawaii Department of Health (21). These estimates were used for the 
Hawaii populations for 1990 through 2005 and estimated for 2006–2010 based on linear 
projections from the 2000 through 2005 data.
County-level population estimates were used for sub-state SEER regions. The Census 
Bureau does not disclose race/ethnic-specific population counts below 100 for any 
geographic area (22). When Census population data were suppressed for an AANHPI 
population for an entire registry, the registry was excluded from rate calculations for that 
particular group. When population data were suppressed for some counties within a 
multicounty metropolitan region, rates were calculated for the remaining counties with 
available population data (Supplementary Table S1). Population counts for each AANHPI 
population by SEER region for the three censal years are shown in Table 1.
Statistical analysis
Lung cancer histologic cell-type–specific incidence rates and 95% confidence intervals (CI) 
were calculated as cases per 100,000 persons and age-adjusted to the 2000 U.S. standard 
population using SEER Stat software (http://seer.cancer.gov/seerstat/). Rates were 
suppressed for case counts <10 (23). Annual rates are shown graphically as trends (24, 25), 
except for smaller groups, where 2 or 5 year averaged rates are shown (Figs. 1 and 2). 
Joinpoint regression models and annual percentage change (APC) statistics (two-side P 
values) were used to characterize the magnitude and direction of trends (26). A maximum of 
three joinpoints were allowed on the basis of single year data. Plots of rate estimates and 
trend lines produced by the joinpoint analysis are shown in semi-logarithmic scale and 2:1 
y:x axis aspect ratio for comparison of trends by histology among populations (24, 25).
Results
Characteristics of lung cancer cases
Table 2 describes the characteristics of incident lung cancer cases diagnosed from 1990 
through 2010. With the exception of Japanese and native Hawaiians, the majority of cases 
were diagnosed in California. Adenocarcinoma was the most common histologic cell type, 
followed by unspecified types and SCC across all racial/ethnic groups.
Lung cancer incidence trends in males
Among NHW men, incidence rates for most histologic cell types declined overall, with the 
exceptions of SCC and adenocarcinoma, which showed a slight upward trend after 2004 
(Fig. 1; Table 3). SCLC showed a significantly steady −3.3% (95% CI, −3.5 to −3.1) decline 
per year, while rates for LC+OSC showed a −4.1% (95% CI, −4.8 to −3.5) decrease per year 
from 1990 through 1999, followed by a steep decline of −10.3% (95% CI, −18 to −2.4) per 
year from 1999 through 2002, and then slowing down to −3.5% (95% CI, −4.5 to −2.5) 
decrease per year thereafter. Unlike trends for other histologic cell types, rates for 
Cheng et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
unspecified types were stable from 1990 through 1997, then increased 3.5% (95% CI, 2.2 to 
4.8) per year from 1997 through 2003, followed by a decrease of −4.0% (95% CI, −5.7 to 
−2.3) per year from 2003 to 2008, and then a much steeper decrease of −17% (95% CI, −22 
to −11) per year from 2008 through 2010.
Overall, lung cancer incidence trends in Chinese men declined during the period 1990–2010, 
with the exception of a slight 1.3% increase (95% CI, 0 to 2.5) in adenocarcinoma from 
1996 through 2010. Rates of unspecified types declined dramatically by −18% per year 
(95% CI, −34.5 to 3.0) from 2007 through 2010. For SCC, incidence rates also declined 
overall, with the steepest decline observed from 1990 through 2001 (APC = −6.8; 95% CI, 
−9 to −4.6). Chinese men also experienced a significant annual decrease of SCLC (APC 
1990-2010 = −2.7; 95% CI, −4.1 to −1.3) and a more striking decrease in LC+OSC (APC 
1990-2010 = −5.7; 95% CI, −7.1 to −4.4).
For Filipino men, trends in adenocarcinoma were stable; however, incidence of unspecified 
types increased significantly from 1990 through 2000 (APC = 7.5; 95% CI, 3.9 to 11.4) and 
declined sharply from 2000 through 2010 (APC = −4.2; 95% CI, −6.7 to −1.6). From 1990 
through 2010, Filipino men also experienced a statistically significant annual decrease in 
SCC (APC = −2.5; 95% CI, −3.5 to −1.6), SCLC (APC = −3.3; 95% CI, −4.4 to −2.1), and 
LC+OSC (APC = −5.3; 95% CI, −7.2 to −3.3).
Although Japanese men experienced stable rates of adenocarcinoma from 1990 through 
2010, they experienced a statistically significant −4.4% (95% CI, −6.1 to −2.7) annual 
decrease in LC+OSC. Incidence rates of unspecified types showed a divergent trend unlike 
those seen in the other four histologic cell types, with a statistically significant increase of 
3.7% (95% CI, 1.8 to 5.5) per year from 1990 through 2006 followed by a nonsignificant 
decrease of −8.3% per year from 2006 through 2010.
Overall, incidence rates in Korean men significantly declined for two of five histologic cell 
types from 1990 through 2010, with a −3.0% (95% CI, −4.7 to −1.2) annual decrease for 
unspecified types and a −4.8% (95% CI, −6.7 to −2.8) annual decrease for SCC.
During 1990-2010, Vietnamese men experienced marked declines in SCC (APC = −4.3; 
95% CI, −7.9 to −0.7), SCLC (APC = −3.9; 95% CI, −6.5 to −1.2), and LC+OSC (APC = 
−7.3; 95% CI, −10 to −4.4). From 2006 through 2010, a large, nonsignificant increase in the 
incidence rate of adenocarcinoma was observed in Vietnamese men (APC = 11.0; 95% CI, 
−1.5 to 24.2). For native Hawaiian men, incidence rates for adenocarcinoma were stable. 
However, they experienced declining trends for unspecified types (APC 2003-2010 = −8.8; 
95% CI, −15 to −2.1), SCC (APC 1990-2010 = −3.9; 95% CI, −5.8 to −2.0), and SCLC 
(APC 1990-2010 = −4.3; 95% CI, −6.7 to −1.9). Histologic data for Laotian men were 
sparse for all cell types and are not shown in Fig. 1 and Table 3, except for adenocarcinoma, 
whose rates showed a nonsignificant increase from 1990 through 2010. In contrast, 
Kampuchean men experienced slight decreasing trends in adenocarcinoma and unspecified 
types (albeit insignificant). Samoan men also experienced a nonsignificant decreasing trend 
in rates of adenocarcinoma, but stable rates in unspecified types and SCC. Although Asian 
Indian/Pakistani men had stable rates of unspecified types and SCLC, they experienced a 
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nonsignificant annual decrease of −1.9% (95% CI, −8.7 to 5.3) in SCC, an annual decrease 
of −5.4% (95% CI, −21 to −13) in LC+OSC, and a nonsignificant annual increase of 2.2% 
(95% CI, −0.2 to 4.7) for adenocarcinoma from 1990 through 2010.
Lung cancer incidence trends in females
Among NHW women, adenocarcinoma and SCC were the only histologic cell types to show 
overall increasing trends from 1990 through 2010 (Fig. 2; Table 4). Incidence rates for 
adenocarcinoma increased 1.5% (95% CI, 1.0-2.1) per year from 1990 through 1998, 
appeared stable 1998–2004, then increased again from 2004 through 2010 (APC = 2.3%; 
95% CI, 1.5-3.1). Rates for SCC decreased −2.5% (95% CI, −3.5 to −1.6) per year from 
1996 through 2004 and increased 2.2% (95% CI, 0.9-3.4) per year from 2004 through 2010. 
Rates for unspecified types showed the largest decline of all histologic cell types, 
significantly decreasing −15.6% (95% CI, −20 to −10) per year from 2008 through 2010.
From 1990 through 2010, Chinese women experienced statistically significant decreases in 
incidence rates of three histologic cell types: −5.8% (95% CI, −7.8 to −3.8) annual decrease 
for SCLC, −4.3% (95% CI, −6.8 to −1.8) annual decrease for SCC, and −5.5% (95% CI, 
−8.2 to −2.7) annual decrease for LC+OSC. Trends in rates for adenocarcinoma were 
relatively stable (APC = 0.3; 95% CI, −0.4 to 1.1).
For Filipino women, trends showed increasing rates for adenocarcinoma (APC 1990-2010 = 
2.6; 95% CI, 1.7-3.5) and unspecified types (APC 1990-2005 = 4.0; 95% CI, 1.7-6.3), and 
decreasing rates for SCC (APC = −3.8; 95% CI, −5.8 to −1.8).
For Japanese women, slight increasing trends were observed for adenocarcinoma and SCLC, 
whereas decreasing trends were observed for LC+OSC (albeit insignificant). For unspecified 
types, rates significantly increased 6.6% (95% CI, 4.2 to −9) per year from 1990 through 
2005 but showed a nonsignificant −8.2% (95% CI, −16 to 0.1) decrease per year from 2005 
through 2010. Rates for SCC significantly increased 2.4% (95% CI, 0.7 to 4.2) per year from 
1990 through 2010.
Like Filipino women, Korean women experienced a statistically significant increase in 
adenocarcinoma from 1990 through 2010 (APC = 3.0; 95% CI, 1.6 to 4.4) and decreasing 
rates for SCC (APC = −2.8; 95% CI, −3.7 to −1.9). For Vietnamese women, trends in 
incidence rates significantly declined for three histologic cell types from 1990 through 2010: 
SCLC (APC = −8.7; 95% CI, −11 to −6.4), SCC (APC = −7.3; 95% CI, −12 to −2.3), and 
LC+OSC (APC = −6.8; 95% CI, −11 to −2). Incidence rates for adenocarcinoma were 
otherwise stable (APC = 0.5; 95% CI, −1.1 to 2.1).
Native Hawaiian women were the only AANHPI population to experience a statistically 
significant decline in adenocarcinoma with a −1.7% decrease in incidence per year (95% CI, 
−3.1 to −0.2) from 1990 through 2010. Rates for all other histologic types showed 
nonsignificant declines during this period.
For Kampuchean, Samoan, and Asian Indian/Pakistani women, there were too few cases to 
show trends in incidence rates for most histologic cell types, except for adenocarcinoma, 
whose trends were stable for these populations from 1990 to 2010.
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Summary of trends by histologic cell type
Overall, incidence trends of adenocarcinoma increased in Chinese men and in Filipino and 
Korean women, decreased in NH women, and remained stable in Chinese women.
For unspecified types, the trends in rates for men started increasing in 1990 but showed a 
marked decline in Filipinos, native Hawaiians, and NHWs in the years thereafter, with the 
decline beginning in 2000 for Filipino men, in 2003 for NH men, and in 2003 for NHW 
men. Korean men experienced a slow and steady decline in unspecified types during 
19902010. Similar to men, trends in unspecified types for women significantly increased in 
Filipino, Japanese, and NHW women from 1990 through the mid-2000s, followed by a 
significant decline thereafter in NHW women.
For SCC, overall trends were declining or stable in men and women across all AANHPI 
populations, with the exception of increasing rates of SCC in Japanese women. SCLC trends 
were also declining or stable in men and women across all AANHPI groups and NHWs, 
with the greatest declines observed in Vietnamese women and NH men.
Finally, trends in LC+OSC showed modest declines among all histology cell types for 
almost all AANHPI populations in men and women.
Discussion
Using 21 years of cancer incidence data from SEER, this study is the first to present 
population-based data describing detailed trends in lung cancer incidence by histologic cell 
type across ten AANHPI populations. Although lung cancer incidence has declined overall 
in the United States and worldwide in men, with stable rates in women, findings from this 
study show marked differences in trends by histologic cell type across AANHPI populations. 
We observed notable significant increases in adenocarcinoma in Filipino and Korean 
women, similar to NHW women, and increases in SCC among Japanese women, whereas 
trends in rates for other histologic cell types (unspecified, SCC, SCLC, and LC+OCS) were 
declining or stable in most AANHPI populations and NHWs. More recently, rates of 
adenocarcinoma also appeared to be slightly increasing in Chinese and NHW men. These 
findings suggest the importance of disaggregating data among AANHPI populations to 
identify vulnerable groups who may experience disparate trends, thus aiding public health 
prevention efforts to target those groups in greatest need.
The steadily increased trend of adenocarcinoma among Chinese men since 1996, the 
dramatically increasing trend among Vietnamese men (albeit not statistically significant), the 
significantly increased rates among Filipino and Korean women, and the stable rates among 
Chinese women point to the growing burden of adenocarcinoma among these Asian 
American populations. Data on Asian countries from the International Agency for Research 
on Cancer (Volumes VII-Volume IX from 1988-2002) indicate large increases in the 
incidence trends of lung adenocarcinoma for Chinese men (APC = 7.0) and Filipino and 
Korean women (APC = 8.1 and 3.6, respectively), while a somewhat stable trend was 
estimated (APC = 1.0) for Chinese women (data not shown). These data from Asia also 
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point to the growing burden of lung adenocarcinoma among these particular Asian 
populations.
Possible reasons underlying the trends demonstrated here may be due to the persistence of 
exposure to lung cancer carcinogens among these AANHPI populations. Adenocarcinoma is 
more weakly associated with smoking than other histologic cell types such as SCC and 
SCLC (27, 28), indicating that other exposures are particularly relevant for this cell type as 
well as genetic susceptibility (29-32). Interestingly, the increasing incidence rates of 
adenocarcinoma were seen among some of the more recent Asian American immigrants to 
the United States— Vietnamese, Laotian, and Asian Indian/Pakistani men and Filipino and 
Korean women. It is possible that higher prevalence of exposures found among immigrant 
groups (33, 34) that have been linked to adenocarcinoma such as preexisting tuberculosis 
infection (35) may play a role in the increasing rates of disease. On the basis of the 2002–
2005 National Survey on Drug Use and Health, the prevalence of smoking varied greatly 
between Asian American men and women (12). For men, the prevalence of smoking within 
the past 30 days was 16.1% in Chinese men and 33.5% in Vietnamese men (12). For women, 
the prevalence of smoking within the past 30 days was highest in Korean women at 20.1% 
out of six Asian American populations followed by Filipinas at 10.4%, and was low among 
other groups (12). Acculturation, the process by which foreign-born individuals adopt 
values, customs, attitudes, and behaviors of the mainstream culture (36, 37), has been 
reported to differentially influence smoking behavior among Asian American men and 
women (38). This has important implications on the underlying factors affecting lung cancer 
development among these populations. In particular, a meta-analysis study reported that 
acculturated Asian American men were roughly 50% less likely to smoke than less 
acculturated men (38). In contrast, acculturated Asian American women were five times 
more likely to smoke than less acculturated women (38). Our previous work confirms this 
pattern as we have reported lower rates of smoking in U.S.-born Asian American men in 
comparison with foreign-born Asian American men, yet an opposite pattern by nativity was 
seen for Asian American women (39). This suggestion that acculturation may have 
beneficial effects on smoking behavior in Asian American men yet a harmful effect in Asian 
American women (38, 39) is an important consideration for future etiologic and tobacco 
prevention studies of lung cancer among Asian Americans.
The rise in adenocarcinoma rates may be due to other contributing factors such as second 
hand tobacco smoke, diet and cooking methods, and previous lung diseases as highlighted 
by studies conducted in Asia, and particularly in epidemiologic studies of Asian women 
given their lower rates of smoking and higher rates of lung cancer (40–42). Among never 
smoking Chinese women, environmental tobacco smoke from the home or workplace and 
the use of coal for household heating and cooking, which is a source of carcinogenic 
polycyclic aromatic hydrocarbons, were estimated to account for 25% and nearly 20% of 
lung cancer cases, respectively (43). Previous lung diseases contribute to a significant 
proportion of lung cancer in Chinese never-smokers, with tuberculosis accounting for a 
greater proportion of the burden of lung cancer in China (43). Although these studies in Asia 
provide important insight on the risk factors for lung cancer among Asian populations, the 
prevalence of these factors is likely considerably lower among the Asian American 
population in the United States. Previous work conducted among AANHPIs from Hawaii 
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observed an increased risk of lung cancer unrelated to smoking among Chinese women, 
indicating that other etiologic factors may be responsible and additional investigation is 
needed (44). Conducting etiologic studies of lung cancer risk among AANHPIs is an 
important research priority given the growing Asian American population, our limited 
knowledge of the underlying risk factors, and as this report exemplifies, their steady and 
increasing trends of adenocarcinoma in specific populations.
The steady decline in rates of LC+OSC was consistent for men and women across nearly all 
AANHPI populations. The decline in LC+OSC was greatest among Vietnamese men, whose 
prevalence of smoking is among the highest of all racial/ethnic groups (12), and may be 
correlated with declining prevalence of smoking in California (45).
For unspecified types, incidence trends seemed to increase among most AANHPIs through 
the 1990s and 2000s, with a marked decline beginning around the early-to mid-2000s. Such 
a notable trend around a similar time-frame across most populations suggests the possibility 
of a systematic change in coding practices that may lead to improved specificity of 
unspecified types to being coded to more specific histologic cell types. Indeed, beginning 
with bevacizumab in 2005 (46), the development of lung cancer therapeutic agents restricted 
to specific histologies has led to an increased emphasis of histologic subtyping and a focused 
effort to reduce histologically unspecified diagnoses. However, this divergent trend was not 
observed for Vietnamese, Korean, Kampuchean, Samoan, and Asian Indian/Pakistani men or 
Korean women. Continued surveillance in trends of unspecified histologic cell types after 
2010, given the new classification codes issued in 2011 (47), may provide further insight 
into explanations for these trends.
It has been suggested that these changes in histology practices and coding systems for 
unspecified types may result in artifactual trends in histologic specific cell types such as the 
increasing trends for adenocarcinoma and SCC starting around 2005 (48). In our study, the 
declining trends in unspecified types (~2000s) did not correspond with the increasing trends 
for adenocarcinoma and SCC (mostly 1990–2010), indicating our findings may not be 
largely biased by such changes in histologic diagnosis.
There are several caveats worth noting. First, because data on race/ethnicity are primarily 
derived from medical records (17), they may be misclassified; however, prior research shows 
low to moderate misclassification for AANHPIs, highest among Vietnamese and South 
Asians (sensitivity < 50%) but >75% sensitivity among other Asian American populations 
(17, 49–55). Second, rates may be underestimated because of exclusion of cases coded as 
“Asian, not otherwise specified.” Third, there may be errors associated with the inter-censal 
annual population estimates (56). Fourth, small case and denominator counts in some groups 
lead to unstable rates and potential trends that could not be detected. Finally, many of these 
patterns could be attributable to cohort changes in acculturation over time, which could not 
be assessed.
Despite these potential limitations, this report based on robust national data covering more 
than half of the Asian American population and two-thirds of the NHPI population, provides 
important insight on contemporary histologic cell-type–specific lung cancer trends among 
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ten AANHPI populations in the United States, serving as a basis of critical evidence to 
inform future research and health policies. Although the declines in adenocarcinoma among 
most groups of AANHPI males mirror the trends seen among NHW males, the increasing 
trends among Filipino and Korean females and Chinese men are of particular concern. Also, 
the increase in SCC among Japanese females is of concern. These results point to areas 
where targeted preventive efforts for tobacco prevention and control can be undertaken now 
in public health, policy, and clinical arenas. Furthermore, given the low smoking prevalence 
among specific Asian American females and few known lung cancer risk factors in U.S. 
never-smoker populations, additional research of etiologic factors, focused especially on 
these ethnic groups of Asian American females, may elucidate knowledge and progress 
against lung cancer among never smokers.
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Figure 1. 
Male trends of lung cancer incidence rates and APC by race/ethnicity and histological cell 
type, 1990–2010, United States.
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Figure 2. 
Female trends of lung cancer incidence rates and APC by race/ethnicity and histologic cell 
type, 1990–2010, United States.
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Table 3
Male trends of lung cancer incidence rates and APC by race/ethnicity and histologic cell type, 1990–2010, 
United States
SCLC Adenocarcinoma SCC LC and OSC Unspecified
NHW
 1990–2010 −3.3a (−3.5 to 
−3.1)
1990–1998 −0.2 (−0.7 to 0.4) 1990–1995 −5.1a 
(−5.8 to −4.3)
1990–1999 −4.1a 
(−4.8 to −3.5)
1990–1997 0.3 (−0.5 to 
1.2)
1998–2004 −2.9a (−4 to 
−1.7)
1995–1999 −2.6a 
(−4.5 to −0.7)
1999–2002 −10.3a 
(−18 to −2.4)
1997–2003 3.5a (2.2 to 
4.8)
2004–2010 1.5a (0.7 to 2.4) 1999–2004 −5.4a 
(−6.7 to −4.2)
2002–2010 −3.5a 
(−4.5 to −2.5)
2003–2008 −4.0a (−5.7 
to −2.3)
2004–2010 1.0a 
(0.3 to 1.7)
2008–2010 −17a (−22 to 
−11)
Chinese
 1990–2010 −2.7a (−4.1 to 
−1.3)
1990–1996 −5.5a (−11 to 
−0.1)
1990–2001 −6.8a 
(−9 to −4.6)
1990–2010 −5.7a 
(−7.1 to −4.4)
1990–2007 1.8(0 to 3.6)
1996–2010 1.3a (0 to 2.5) 2001–2010 −1.4 (−4.3 to 1.5)
2007–2010 −18 (−34 to 
3.0)
Filipino
 1990–2010 −3.3a (−4.4 to
−2.1)
1990–2010 0.3 (−0.4 to 1.0) 1990–2010 −2.5a 
(−3.5 to−1.6)
1990–2010 −5.3a 
(−7.2 to −3.3)
1990–2000 7.5a (3.9 to 
11.4)
2000–2010 −4.2a (−6.7 
to −1.6)
Japanese
 1990–2010 −0.7 (−2.4 to 
1.1)
1990–2010 0.1(−0.9 to 1.1) 1990–2010 
−1.2(−2.4 to 0.1) 1990–2010
b
 −4.4a 
(−6.1 to −2.7)
1990–2006 3.7a (1.8 to 
5.5)
2006–2010 −8.3 (−19 to 
3.7)
Korean
 1990–2010b −3.2 (−6.5 to 
0.3)
1990–2010b −1.1 (−2.6 to 
0.5)
1990–2010 −4.8a 
(−6.7 to −2.8)
1990–2010c −3.4 
(−19 to 15)
1990–2010 −3.0a (−4.7 
to−1.2)
Vietnamese
 1990–2010b −3.9a (−6.5 to 
−1.2)
1990–2006 −1.4 (−3.7 to 1.0) 1990–2010b −4.3a 
(−7.9 to −0.7)
1990–2010b −7.3a 
(−10 to −4.4)
1990–2010b −0.7 (−4.7 
to 3.4)
2006–2010 11 (−1.5 to 24.2)
Native Hawaiian
 1990–2010b −4.3a (−6.7 to
−1.9)
1990–2010 0.1 (−1.0 to 1.3) 1990–2010 −3.9a 
(−5.8 to −2.0)
1990–2010c −7.5 
(−18 to 3.8)
1990–2003 2.2 (−1.1 to 
5.6)
2003–2010 −8.8a (−15 to 
−2.1)
Laotian
1990–2010c 1.5 (−4.7 to 8.1)
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SCLC Adenocarcinoma SCC LC and OSC Unspecified
Kampuchean
1990–2010c −0.7 (−11 to 11) 1990–2010c −2.7 (−13 to 
9.2)
Samoan
1990–2010c −1.1 (−7.4 to 
5.5)
1990–2010c −0.1 
(−6.5 to 6.6)
1990–2010c −0.1 (−7.3 
to 7.7)
Asian Indian/Pakistani
1990–2010c −0.2 (−5.7 to 5.6) 1990–2010b 2.2 (−0.2 to 4.7) 1990–2010c −1.9 
(−8.7 to 5.3)
1990–2010c −5.4 
(−21 to 13)
1990–2010c 0.1 (−5.0 to 
5.4)
a
The 95% CI for the APC does not include zero (P < 0.05).
bJoinpoint and observed rates are based on 2-year groups.
cJoinpoint and observed rates are based on 5-year groups.
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Table 4
Female trends of lung cancer incidence rates and APC by race/ethnicity and histologic cell type, 1990–2010, 
United States
SCLC Adenocarcinoma SCC LC and OSC Unspecified
NHW
 1990–2010 −1.9a (−2.1 to 
−1.7)
1990–1998 1.5a (1 to 2.1) 1990–1996 0 (−1.2 to 
1.2)
1990–1997 −1 (−2 to 
0) 1990–2002 4.4
a
 (4 to 
4.8)
1998–2004 −0.7 (−1.7 to 
0.4) 1996–2004 −2.5
a 
(−3.5 to −1.6)
1997–2003 −5.2a 
(−6.9 to −3.4)
2002–2005 2.0 (−3.0 to 
7.2)
2004–2010 2.3a (1.5 to 3.1) 2004–2010 2.2a (0.9 
to 3.4)
2003–2010 −0.8 (−2 
to 0.3) 2005–2008 −5.4
a
 (−10 to 
−0.5)
2008–2010 −15.6a (−20 
to −10)
Chinese
 1990–2008b −5.8a (−7.8 to 
−3.8)
1990–2010 0.3 (−0.4 to 1.1) 1990–2008b −4.3a 
(−6.8 to −1.8)
1990–2008b −5.5a 
(−8.2 to −2.7)
1990–2006 2.2 (−0.2 to 
4.6)
2006–2010 −13.1 (−24.7 
to 0.2)
Filipino
 1990–2008b −2.0 (−4.2 to 
0.2)
1990–2010 2.6a (1.7 to 3.5) 1990−2008b −3.8a 
(−5.8 to −1.8)
1990–2008b −1.9a 
(−3.5 to −0.3)
1990–2005 4.0a (1.7 to 
6.3)
2005–2010 −5.1 (−11.9 
to 2.3)
Japanese
 1990–2010 0.9 (−1 to 2.9) 1990–2010 1.0 (−0.1 to 2) 1990–2010 2.4a (0.7 
to 4.2)
1990–2010b −1.4 
(−4.5 to 1.9)
1990–2005 6.6a (4.2 to 
9)
2005–2010 −8.2 (−16 to 
0.1)
Korean
 1990–2010c −4.7 (−1310 
4.3)
1990–2010b 3.0a (1.6 to 4.4) 1990–2010c −2.8a 
(−3.7 to −1.9)
1990–2010c 1.8 (−5.7 to 
10)
Vietnamese
 1990–2010c −8.7a (−11 to 
−6.4)
1990–2010 0.5 (−1.1 to 2.1) 1990–2010c −7.3a 
(−12 to −2.3)
1990–2010c −6.8a 
(−11 to −2)
1990–2004b 3.5 (−2.8 to 
10)
2004–2010 −18 (−40.7 
to 13)
Native Hawaiian
 1990–2010b −1.8 (−3.7 to 
0.1)
1990–2010 −1.7a (−3.1 to 
−0.2)
1990–2002b 1.9 (−2.9 
to 7.1)
1990–2010c −3.0 
(−16 to 12)
1990–2007 −0.3 (−2.9 to 
2.5)
2002–2010 −10 (−20 
to 1.2)
2007–2010 −29.2 (−52 
to 4.2)
Kampuchean
1990–2010c −0.2 (−5.9 to 
5.8)
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SCLC Adenocarcinoma SCC LC and OSC Unspecified
Samoan
1990–2010c −0.5 (−13 to 
14)
Asian Indian/Pakistani
1990–2010c −0.4 (−8.6, to 
8.5)
a
The 95% CI for the APC does not include zero (P < 0.05).
bJoinpoint and observed rates are based on 2-year groups.
cJoinpoint and observed rates are based on 5-year groups.
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